Breast cancer [advanced]; non-small cell lung cancer [advanced].
Monotreatment: 25-30mg/m2 weekly. Combination therapy: 25-30mg/m2 on day 1 and 8, repeated after 21 days [IV admin].
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
A vinca alkaloid that binds to tubulin [the protein subunit of the microtubules that form the mitotic spindle] forming complexes that prevent the polymerization of the tubulin subunits into microtubules. It also induces depol-ymerization of microtubules. These actions lead to inhibition of microtubule assembly and cellular metaphase arrest.
Avoid extravasation as it causes marked irritation; it is fatal when given intrathecally.
Hypersensitivity to the drug
Alopecia; nausea and vomiting; abdominal pain; constipation; chest pain; respiratory system disorders; neuropathy [both peripheral & autonomic]; paralytic ileus; vestibular and auditory nerve damage; myelosuppression